Wuxi Biologics (Cayman), Inc. (2269) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wuxi Biologics (Cayman), Inc.

3SBio, Inc.

Alphamab Oncology

CSPC Pharmaceutical Group Ltd.

Sirnaomics Ltd.

Zai Lab Ltd.

AIM Vaccine Co., Ltd.

Ascentage Pharma Group International Co., Ltd.

Laekna, Inc.

Beijing Lüzhu Biotechnology Co., Ltd.

Genscript Biotech Corp.

Why is Wuxi Biologics (Cayman), Inc. ?

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 47.82

Healthy long term growth as Net Sales has grown by an annual rate of 35.21% and Operating profit at 41.97%

Flat results in Dec 24

INTEREST(Q) Highest at HKD 97.1 MM

With ROE of 9.88%, it has a Fair valuation with a 3.06 Price to Book Value

Over the past year, while the stock has generated a return of 81.76%, its profits have risen by 8.3% ; the PEG ratio of the company is 2.9

Market Beating Performance

The stock has generated a return of 81.76% in the last 1 year, much higher than market (Hang Seng Hong Kong) returns of 26.67%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Wuxi Biologics (Cayman), Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Wuxi Biologics (Cayman), Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Wuxi Biologics (Cayman), Inc.

84.36%

3.42

56.82%

Hang Seng Hong Kong

27.36%

1.03

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

35.21%

EBIT Growth (5y)

41.97%

EBIT to Interest (avg)

47.82

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.19

Sales to Capital Employed (avg)

0.36

Tax Ratio

18.39%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

13.03%

ROE (avg)

9.46%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.06

EV to EBIT

25.73

EV to EBITDA

18.90

EV to Capital Employed

3.54

EV to Sales

6.32

PEG Ratio

2.85

Dividend Yield

ROCE (Latest)

13.78%

ROE (Latest)

9.88%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Wuxi Biologics (Cayman), Inc.

Operating Cash Flow

Highest at HKD 10,859.33 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Inventory Turnover Ratio

Highest at 6.49% and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales

Highest at HKD 10,957.87 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Operating Profit

Highest at HKD 3,950.05 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at 36.05 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at HKD 3,237.98 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Pre-Tax Profit

At HKD 3,237.98 MM has Grown at 81.66%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

At HKD 2,146.48 MM has Grown at 74.77%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

Debtors Turnover Ratio

Highest at 2.86%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -3.77% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at HKD 949.66 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation

At HKD 949.66 MM has Grown at 11.81%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Wuxi Biologics (Cayman), Inc.

Interest

Highest at HKD 97.1 MM

in the last five periods and Increased by 31.64% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)